Press Brief

CLIMB THAL-111 and CLIMB SCD-121: exa-cel gene therapy in TDT and SCD

Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL

Venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13

10-day decitabine vs 3+7 chemotherapy followed by alloHSCT in older & fit patients with AML

Update on QuANTUM-First: quizartinib + SOC chemotherapy & as continuation therapy in FLT3-ITD+ AML

Safety & efficacy of ARI0002H in R/R multiple myeloma

Antibody responses to COVID-19 vaccines in patients with hematological malignancies

Beti-cel gene therapy for transfusion-dependent β-thalassemia: 7-year follow up data

CHIP is robustly associated with protection from Alzheimer’s disease

Pivotal findings from a Phase I/II trial of mosunetuzumab monotherapy for R/R follicular lymphoma

TRANSFORM: Phase III study of liso-cel versus standard of care for R/R LBCL

Phase III trial of RVd induction with or without isatuximab in newly diagnosed myeloma

Investigating rates of COVID-19 infection in patients with sickle cell disease

Predicting outcomes for patients with leukemia and MDS after COVID-19 infection

COVID-19 risk factors in patients with hematologic malignancies

Responses to COVID-19 vaccines in patients with AML and MDS